Maliheh Barzegari1, Parvin Sarbakhsh2, Majid Mobasseri3, Hamid Noshad4, Asra Esfandiari1, Behnam Khodadadi5, Bahram Pourghassem Gargari6. 1. Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Chronic Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Department of Nutrition, Nutrition Research & Food Research Institute of Iran, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: pourghassemb@tbzmed.ac.ir.
Abstract
AIMS: Diabetic nephropathy is one of the major microvascular complications of type 2 diabetes which insufficient vitamin D might -have a role in it's incidence. This study evaluated the effects of vitamin D supplementation on lipid profiles and oxidative/anti-oxidative indices in marginal vitamin D status patients with diabetic nephropathy. METHODS: For the current paralleled, randomized, double-blinded, placebo-controlled clinical trial, 50 diabetic nephropathy patients with marginal serum vitamin D were selected. Intervention group received 1,25-dihydroxycholecalciferol (50000 IU/week, n = 25), and placebo group (n = 25) received an identical placebo, for 8 weeks. Lipid profiles (LDL, HDL, TG and TC) and oxidative/anti-oxidative markers (TAC, SOD, CAT, GPX and MDA) were measured. RESULTS:Vitamin D supplementation significantly increased vitamin D status in the intervention group, compared to the control group (P = 0.001). The reductions in the serum levels of TG, LDL and TC were significant (P = 0.04, P = 0.006 and P = 0.02, respectively) in the intervention group. The changes in oxidative/anti-oxidative markers and HDL levels were not significant after intervention. CONCLUSION: In conclusion, vitamin D supplementation for 8 weeks among diabetic nephropathy patients has beneficial effects on serum vitamin D status and dyslipidemia.
RCT Entities:
AIMS: Diabetic nephropathy is one of the major microvascular complications of type 2 diabetes which insufficient vitamin D might -have a role in it's incidence. This study evaluated the effects of vitamin D supplementation on lipid profiles and oxidative/anti-oxidative indices in marginal vitamin D status patients with diabetic nephropathy. METHODS: For the current paralleled, randomized, double-blinded, placebo-controlled clinical trial, 50 diabetic nephropathypatients with marginal serum vitamin D were selected. Intervention group received 1,25-dihydroxycholecalciferol (50000 IU/week, n = 25), and placebo group (n = 25) received an identical placebo, for 8 weeks. Lipid profiles (LDL, HDL, TG and TC) and oxidative/anti-oxidative markers (TAC, SOD, CAT, GPX and MDA) were measured. RESULTS:Vitamin D supplementation significantly increased vitamin D status in the intervention group, compared to the control group (P = 0.001). The reductions in the serum levels of TG, LDL and TC were significant (P = 0.04, P = 0.006 and P = 0.02, respectively) in the intervention group. The changes in oxidative/anti-oxidative markers and HDL levels were not significant after intervention. CONCLUSION: In conclusion, vitamin D supplementation for 8 weeks among diabetic nephropathypatients has beneficial effects on serum vitamin D status and dyslipidemia.
Authors: Laine de Carvalho Guerra Pessoa Mamede; Rafaela Lira Formiga Cavalcanti de Lima; Alexandre Sérgio Silva; João Carlos Lima Rodrigues Pita; Nadjeanny Ingrid Galdino Gomes; Elisama Araújo de Sena; Rhayra Priscila Moraes Nobrega; João Otávio Scarano Alcântara; Julie Hanna Fontes de Souza; Glêbia Alexa Cardoso; José Luiz de Brito Alves; Maria da Conceição Rodrigues Gonçalves Journal: Diabetes Metab Syndr Obes Date: 2021-02-04 Impact factor: 3.168